Penumbra Inc (PEN)

Industry Medical Devices


This stock can be held in an Investment ISA and an Investment Account
Sell

$250.00

Buy

$281.00

arrow-up$1.79 (+0.67%)

Prices updated at 23 May 2025, 22:03 EDT
| Prices minimum 15 mins delay
|
Prices in USD

Penumbra Inc designs, develops, manufactures and markets medical devices. The products of the company address ischemic stroke, hemorrhagic stroke and vascular conditions that can be treated through thrombectomy and embolization procedures.
Sector
Healthcare
Industry
Medical Devices
Chairman
Mr. Adam Elsesser
CEO
Mr. Adam Elsesser
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
4,500
Head office
One Penumbra Place
Alameda
United States
94502
mobile
+1 510 748-3200
letter
investors@penumbrainc.com

Key personnel

Salary
Mr. Harpreet Grewal
Independent Director
0.06m
Mr. Thomas C. Wilder, III
Presiding Independent Director
0.08m
Mr. Adam Elsesser
Chief Executive Officer, President and Chairman of the Board
0.63m
Dr. Arani Bose, M.D.
Director
0.05m
Ms. Bridget O'Rourke
Independent Director
0.08m
Ms. Johanna Roberts
Executive Vice President, General Counsel and Secretary
0.70m
Ms. Janet Leeds
Independent Director
0.07m
Ms. Surbhi Sarna
Independent Director
0.07m
Mr. Lambert Shiu
Chief Accounting Officer
0.58m
Ms. Maggie Yuen
Chief Financial Officer
0.70m

Top 5 shareholders

No. of shares
FMR Inc5,840,124
Fidelity Management and Research Company5,840,124
BlackRock Inc4,134,048
Vanguard Group Inc3,675,349
Fidelity SelectCo, LLC3,058,726

Director dealings

Action
26 Dec 2024-
26 Dec 2024-
20 Dec 2024-
20 Dec 2024-
20 Dec 2024-
20 Dec 2024-
20 Dec 2024-
15 Dec 2024-
15 Dec 2024-
15 Dec 2024-
02 Dec 2024-
02 Dec 2024-
02 Dec 2024-
02 Dec 2024-
02 Dec 2024-
29 Nov 2024-
03 Dec 2024-
03 Dec 2024-
20 Nov 2024-
20 Nov 2024-
Please note that past performance is not a reliable indicator of future returns.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.